TB-500 (TB500, TB 500): what the thymosin beta 4 fragment is, what it does, and what the evidence shows

TB-500 is one of the most heavily marketed recovery peptides online, sold in injectable vials with the promise that it speeds recovery after almost any injury. It is also one of the most misdescribed. On vendor sites and in gym forums it is presented as a proven shortcut, usually with the evidence caveats quietly left out. This page puts them back. It explains what TB-500 actually is, how it relates to the natural protein it is named after, what researchers have and have not shown, what is known and unknown about its safety, and what people who use it report, with a primary source for every claim. It is educational only, and nothing here is medical advice. For the broader picture of how these compounds fit together, start with our explainer on what peptides are, and read this alongside our companion overview of BPC-157.

Also written as: TB500, TB 500, TB-500 peptide, TB500 peptide. Often confused with: thymosin beta 4 (also written thymosin beta-4), the full natural protein TB-500 is based on.

What is TB-500?

TB-500 is a synthetic peptide that corresponds to the active fragment of thymosin beta-4, a small protein the human body actually makes. Thymosin beta-4 is a naturally occurring chain of 43 amino acids present in most human cells, and it is one of the most abundant regulators of actin, the protein that builds a cell’s internal scaffolding. TB-500 is not that whole molecule. It is a short synthetic fragment based on the region of thymosin beta-4 spanning roughly amino acids 17 to 23, the segment the research literature associates with actin binding, blood-vessel growth, and cell movement.

Here is a wrinkle that matters for everything below: the name “TB-500” is used loosely, by researchers as well as sellers. A 2026 rat study of tendon healing, for example, describes its test compound as synthetic thymosin beta-4 (TB-500). Most of the literature uses the name for the synthetic fragment, but many products sold online as “TB-500” are labeled as, or actually contain, the full-length 43-amino-acid thymosin beta-4 instead. Because these are unregulated research chemicals, the buyer usually has no reliable way to know which molecule is in the vial. Keep that ambiguity in mind, because it changes how you should read both the science and the safety questions.

One more distinction is worth stating plainly. Thymosin beta-4 is a real, well-characterized human protein with a genuine research literature behind it. TB-500 is a lab-made shortcut, marketed to reproduce part of that protein’s activity in a cheaper, easier-to-manufacture form. The two are related but not interchangeable, and much of the confusion around TB-500 comes from marketing that treats a study of the natural protein as if it were a study of the vial being sold.

What does TB-500 do?

In animal and cell studies, TB-500 and its parent protein help cells move, organize their internal scaffolding and grow new blood vessels, which is why they are studied for wound and tendon healing. What it does in a human injury is unknown, because no published trial has tested the fragment for that.

The most direct test of the fragment itself is recent and small. In a 2026 study, 32 rats had their Achilles tendons cut and surgically repaired and were split into four groups: no treatment, BPC-157, TB-500, or both. After four weeks, the TB-500 group showed a statistically significant advantage in the force the healing tendon could withstand before failing, along with better scores for tissue structure and collagen organization. The authors called the work exploratory and said both peptides warrant further investigation as candidate adjuncts to tendon repair, pending longer studies. That is a real signal, but it is one rat study with eight animals per group, not evidence about a person’s shoulder or hamstring.

For deeper detail on claimed benefits and reported side effects, our sister site covers TB-500 benefits and side effects in full.

How is TB-500 thought to work?

TB-500 is thought to act mainly by regulating actin and, through it, cell migration and blood-vessel growth, but almost everything known about that mechanism comes from animal and cell experiments rather than human ones. Thymosin beta-4, the parent protein, binds free actin building blocks inside cells and helps control how the actin scaffold assembles and disassembles. According to a 2021 review of the protein, profilin-dependent dissociation of the G-actin and thymosin beta-4 complex liberates actin for filament assembly, the underlying step a cell uses to change shape and move. The same review describes how the protein promotes angiogenesis, enhances endothelial progenitor cell viability, and triggers the proliferation and migration of cells, and how it can raise expression of VEGF, a central signal in the formation of new blood vessels.

The honest framing is that these are proposed, biologically plausible mechanisms seen mostly in rodents and cultured cells, not confirmed pathways of action in a living person. The chain of reasoning that vendors compress into a single confident claim, that the fragment speeds the rebuilding of injured tissue, is really several separate leaps: that the fragment behaves like the full protein, that a mechanism shown in a dish or a mouse operates the same way in a human, and that nudging a cell-level process translates into a faster real-world return from injury. Each leap is assumed, not demonstrated. When a marketing page says TB-500 “works,” what usually sits underneath is an improved measurement in an animal model, which is a genuine scientific observation but not the same thing as a proven effect in people.

What is TB-500 used for?

TB-500 is used mainly for physical recovery: people take it hoping to get back faster from tendon, ligament and muscle injuries and from hard training, often alongside BPC-157. Those uses come from marketing and animal research, not from human trials, so they describe what users hope for rather than what has been shown.

It is important to read that as an area of active interest, not as a settled use, because the wording of an advertisement (“supports faster tendon recovery”) and the wording of the science (“changed a measurement in an animal wound model”) are not the same claim. In the marketing and in the preclinical literature, the interest clusters around a few themes: tendon, ligament, and muscle injury, wound healing, and general connective-tissue recovery, with a secondary set of claims about hair, gut, and cardiovascular health that trace back to properties reported for the parent protein.

Because this overview is the definitional entry point, the network’s deeper, evidence-first pages examine the recovery claims in detail rather than asserting them here:

• Tissue recovery and how the parent protein is studied: how thymosin beta-4 is studied for tissue recovery.
• Compared with the other popular recovery peptide: BPC-157 versus TB-500, and our companion hub overview of BPC-157.
• Taken as a premixed pair: what the Wolverine stack of BPC-157 and TB-500 is.

Treat every one of those areas as “being investigated,” not “established.” The marketing describes the outcome people hope for; the evidence section below describes what has actually been demonstrated. The gap between the two is the entire reason this page exists.

What does the evidence actually show?

Almost all of the evidence behind TB-500 comes from animals and cells, not from humans, and the human data that does exist was not generated with TB-500 at all. This is the single most important thing to understand about the compound. The controlled human trials in this space studied the full-length thymosin beta-4 protein, delivered for specific medical conditions, and they were run for the eye and the heart rather than for sports injuries. In ophthalmology, a randomized phase 2 trial of thymosin beta-4 eye drops in severe dry eye reported a 35.1% reduction in ocular discomfort and a 59.1% reduction in total corneal fluorescein staining versus placebo. In cardiology, a 2025 randomized, placebo-controlled trial gave recombinant human thymosin beta-4 to 96 patients after a heart attack; it saw a reduction in scar size in the subgroup treated early, but the overall difference between the treatment and placebo groups was not statistically significant.

Notice what that means. Even the strongest human evidence for this molecule tests a different substance (the full protein, not the fragment), by a different route (eye drops or a hospital infusion, not self-injection), for a different purpose (dry eye or cardiac recovery, not a torn tendon). None of it establishes that injecting TB-500 speeds recovery from a musculoskeletal injury. For that specific use, there is no completed, published randomized controlled trial in humans at all.

The wider peptide literature makes the imbalance concrete. In one systematic review of a comparable recovery peptide, an independent write-up noted that of 544 papers screened, 36 met the inclusion criteria, and 35 of those were in rodents or cells, with only one involving humans in a musculoskeletal context. The pattern for TB-500 is the same shape: a large, genuinely interesting body of animal and laboratory work, and a near-total absence of human efficacy data for the use people actually buy it for.

It is worth being precise about what this does and does not mean. It does not mean TB-500 has been shown not to work. It means the studies that could show whether the fragment does anything useful in an injured human, large, controlled, and published, have simply not been done. Preclinical promise and human proof are different things, and TB-500 sits almost entirely on the promise side of that line. Anyone presenting a rodent result, or a dry-eye trial of the parent protein, as if it were proof that the fragment fixes injuries is skipping the step that actually matters.

What are the reported side effects and safety unknowns?

TB-500’s human safety profile is largely unknown, because the fragment has barely been studied in people. Marketing frequently calls it “well tolerated,” and it is true that animal studies of thymosin beta-4 report relatively few adverse effects. But a low rate of reported effects in rodents is not a human safety record, and the limited human exposure that does exist is to the full-length protein given as eye drops or a monitored hospital infusion, not to months or years of self-administered injections of a fragment. There is no long-term human safety dataset for the way TB-500 is actually used.

Layered on top of that biological uncertainty is a product-quality problem specific to how TB-500 is sold. Because it is not a regulated medicine, the vials shipped by online vendors carry none of the guarantees a pharmacy product does. An independent expert review of the peptide market, which names TB-500 among the compounds sold this way, notes that the “third-party” certificates of analysis vendors point to are often produced by the vendors themselves, and that leaning on those certificates is itself an admission that the normal guardrails of identity, potency, sterility and quality control are absent.

Independent testing shows this is not a hypothetical worry. When one quality-control analysis examined a synthetic research peptide sourced from five different manufacturers, it found that one product was in reality a totally different peptide, and that two-thirds of the rest fell short of research-grade purity. For TB-500 the problem is compounded by the identity ambiguity described earlier: a buyer often cannot tell whether a vial holds the 17-to-23 fragment, the full-length 43-amino-acid protein, a degraded mixture, or something else entirely. If you want to understand what a certificate of analysis can and cannot tell you, our sister publication breaks down how to read a peptide certificate of analysis. So the safety picture carries two layers of uncertainty at once: what the fragment does inside a human body over time, which has not been studied, and whether the vial even contains what the label claims, at the purity and sterility an injection would require.

TB-500 vs thymosin beta 4 vs BPC-157: how the evidence compares

TB-500, full thymosin beta-4 and BPC-157 are often lumped together as “healing peptides,” but the research behind each is different. Only the full thymosin beta-4 protein has been tested in randomized, controlled human trials, and those were for the eye and the heart. TB-500 and BPC-157 rest mostly on animal and cell work.

The practical takeaway is that the strongest human data in this group belongs to a molecule most buyers are not actually injecting, given for conditions they are not treating. For the head-to-head on how lifters use the two recovery peptides, see BPC-157 vs TB-500.

What does TB-500 cost, beyond the price?

TB-500 costs more than the number on the vial, because the buyer also absorbs the uncertainty about what is inside it and whether it does anything. It is not an approved medicine, so it reaches buyers as an unregulated research chemical, without the quality checks an approved drug goes through.

A few cost points come up again and again:

• Purity paperwork. Vendors often lean on certificates of analysis, but a 2026 analysis in The Conversation notes these “third-party” labs are often the vendors themselves, and that the 98 per cent purity they advertise would not meet any reasonable drug standard.
• Paying for a stack. Because TB-500 is so often paired with BPC-157, many buyers pay for two peptides or a premixed blend, even though a controlled rat study of the pair found no added benefit from the combination.
• Paying shapes the verdict. The same analysis points out that when someone has just spent money on a peptide, expectation joins time, rehabilitation and natural fluctuation as reasons they may feel better, so a satisfied buyer is not proof the peptide worked.

Is TB-500 banned in sport?

Yes. Thymosin beta-4 and its derivatives, TB-500 among them, were added as examples of prohibited growth factors under the World Anti-Doping Agency’s S2 class effective with the 2018 Prohibited List, banned at all times, in and out of competition, so any athlete in a tested sport should treat it as off-limits.

What are people saying about TB-500?

TB-500 is mostly discussed as the recovery half of a pair. In 16 posts on X that our community tracker collected between July 14 and 19, 2026, users described it alongside BPC-157 far more often than on its own, and the conversation split into a few clear threads:

• Injury stories. Several users described using TB-500 while recovering from a torn pectoral ligament, a shoulder injury and a fractured humerus, some saying they were back to training within weeks or months. These are individual anecdotes, usually with BPC-157 in the mix, so they cannot separate the peptide’s effect from time and rehab.
• Skeptics. Not everyone is sold. One poster said the BPC-157 and TB-500 combination did less for them than other peptides, and another said they stopped buying blended vials because BPC-157 alone worked better for their soreness.
• Fragment or full protein. Users point out, correctly, that TB-500 is a fragment and not the full 43-amino-acid thymosin beta-4. One poster went further and claimed many products sold as TB-500 actually contain the full chain. We could not verify that claim, but it lines up with the product-identity problems described in the safety section above.
• The stack. TB-500 is framed as the recovery component and BPC-157 as the gut and tissue-repair component. The one controlled test of the pair we found, a 2026 rat study of repaired Achilles tendons, reported that the combination did not add benefit over either peptide alone, and our BPC-157 overview covers that study. Our sister site covers how BPC-157 and TB-500 compare.

These are a small number of self-reports from one platform over less than a week, not evidence that TB-500 works or is safe.

How to think about TB-500

If you are weighing TB-500, the most useful move is to separate the biology from the claims. The biology is real and legitimately interesting: thymosin beta-4 is a genuine human protein with a serious research literature, and TB-500 is a fragment designed to borrow part of its activity. The claims are mostly hope built on animal data and on studies of the parent protein for unrelated conditions, because the human trials that would confirm a recovery benefit for the fragment have not been run. And the product question is real: what is sold as TB-500 is not always what the label says.

If your actual goal is faster recovery from an injury, more resilient tendons and joints, or a return to training without repeated setbacks, start with that goal, ideally with a licensed clinician, who can weigh physical therapy, imaging to find out what is actually wrong, an approved medication, or a structured rehabilitation plan. If you are evaluating any source, our sister publication lists what to ask before you buy any peptide.

Status: Not FDA-approved; sold by some telehealth providers as a compounded prescription. An FDA advisory committee reportedly voted in July 2026 to recommend allowing pharmacies to compound it; nothing has changed yet. What this status means.

Educational information only, not medical advice. Every scientific statement on this page is sourced to the primary references linked above. Updated October 12, 2026.